Health & Pharma Intelligence

Identifying Hormetic Agents that Modestly Slow Aging from Mouse Toxicology Study Data

Mouse toxicology data reanalysis identifies 27 hormetic compounds that modestly extend lifespan in rodents.

Research relevance Offers faculty a cost-effective method to mine existing datasets for longevity candidates, informing grant proposals in translational aging biology, pharmaceutical screening, and regulatory science applications.

Brief: Researchers examined regulatory long-term rodent pesticide toxicology studies from the German Federal Institute for Risk Assessment archive. From 154 qualifying substances tested in large cohorts, 18% significantly increased survival at certain doses, consistent with hormesis mechanisms involving adaptive stress responses. This approach leverages existing mammalian data to identify potential longevity-modulating agents without new dedicated lifespan trials.

Comprehensive structure-based virtual screening of natural products enabling the discovery of new activators of SIRT1

Structure-based virtual screening of natural products identifies novel SIRT1 activators with superior docking and stability profiles compared to resveratrol.

Research relevance Offers faculty new computational scaffolds for SIRT1-related grant applications in longevity and metabolic disease research while updating teaching on structure-based natural product screening methods.

Brief: Researchers performed hierarchical virtual screening of 46,797 natural products from the ZINC database against SIRT1 allosteric sites using the resveratrol-bound crystal structure. Top candidates underwent induced-fit docking, MM-GBSA calculations, and 100 ns molecular dynamics simulations. ZINC000005158607, ZINC000014762741, and ZINC000014762739 emerged as promising scaffolds showing stable interactions with key allosteric residues and the p53-AMC substrate.

Anti-Fibrotic Drug Rentosertib Reduces Proteomic Clock Age in Humans

Rentosertib, a TNIK inhibitor, reduced proteomic clock age in humans during a Phase II idiopathic pulmonary fibrosis trial.

Research relevance Highlights translational potential of TNIK inhibition in longevity-related pathways, informing grant development in aging biology, pharmaceutical research on shared disease-aging targets, and updates for clinical pharmacy curricula on emerging fibrotic and age-modulating therapies.

Brief: In a Phase II trial for idiopathic pulmonary fibrosis, rentosertib demonstrated anti-fibrotic effects and reduced age estimates from multiple proteomic aging clocks. Developed by In Silico Medicine using AI-driven approaches, the drug targets TNIK to modulate mechanisms overlapping with aging pathways. This provides human translational evidence linking anti-fibrotic intervention to potential effects on biological aging markers.

Novartis Ianalumab Two-Year Data at ACR Show Further Improvements in Sjögren’s Disease Activity

Novartis presented two-year data from the NEPTUNUS extension study showing ianalumab further improves disease activity in Sjögren’s.

Research relevance Provides faculty with awareness of late-stage clinical pipeline progress in autoimmune disease, supporting grant development, clinical research teaching, and regulatory monitoring in pharmaceutical sciences.

Brief: The ongoing Phase III NEPTUNUS extension study of ianalumab in Sjögren’s disease demonstrated continued improvements in disease activity scores over two years. Data were presented at the American College of Rheumatology Convergence 2026. Ianalumab is an investigational monoclonal antibody targeting BAFF-R.

Evidence for Cerebrospinal Fluid Flow Through the Brain to Stagnate in Alzheimer's Disease

Cerebrospinal fluid flow through the brain stagnates in Alzheimer's disease due to circulatory dysfunction linked to impaired lipid metabolism.

Research relevance Highlights preclinical mechanisms of glymphatic impairment in neurodegeneration, informing grant development in CNS therapeutics, pharmaceutical research on lipid modulation, and updates for teaching on brain aging and waste clearance.

Brief: In a mouse model of Alzheimer's disease, researchers mapped the decline in glymphatic cerebrospinal fluid drainage, finding it results from dysfunction at specific locations in the brain's circulatory system. This impairment, which hinders removal of metabolic waste including pathological proteins like amyloid-β and tau, appears as a downstream effect of dysfunctional lipid metabolism and excess cholesterol accumulation in the aging brain. The findings highlight glymphatic decline as a key component of brain aging and neurodegeneration.

The Double-Edged Sword of Therapy-Induced Senescence in Cancer Treatment

Therapy-induced senescence from cancer treatments acts as a double-edged sword, promoting initial tumor arrest but driving accelerated aging and cardiovascular issues.

Research relevance Informs translational research on senotherapeutics, longevity mechanisms, and strategies to reduce therapy-related comorbidities in cancer survivors for grant development and clinical pharmacy teaching.

Brief: Cancer therapies like chemotherapy and radiotherapy induce senescence in both malignant and non-malignant cells, halting replication but leading to persistent senescent cell accumulation. This triggers the senescence-associated secretory phenotype (SASP), causing chronic inflammation, endothelial dysfunction, myocardial fibrosis, vascular stiffness, and accelerated biological aging in survivors. Senotherapeutics such as senolytics are highlighted as a potential means to mitigate these long-term effects.

Each article is evaluated by an AI model on five dimensions totalling 0–25. The score reflects the quality and relevance of the evidence — not the importance of the topic alone. Articles are ranked and filtered before appearing in this briefing.